Stock Traders Buy High Volume of Put Options on SPDR S&P Biotech (XBI)

SPDR S&P Biotech (NYSEARCA:XBI) saw unusually large options trading activity on Thursday. Investors purchased 46,978 put options on the company. This represents an increase of approximately 452% compared to the average daily volume of 8,508 put options.

SPDR S&P Biotech (NYSEARCA:XBI) traded up 2.4270% during trading on Tuesday, hitting $75.9599. 3,890,030 shares of the stock traded hands. The company has a 50-day moving average price of $70.31 and a 200 day moving average price of $67.30. SPDR S&P Biotech has a one year low of $49.51 and a one year high of $76.59.

The business also recently declared a quarterly dividend, which will be paid on Monday, June 26th. Shareholders of record on Tuesday, June 20th will be given a dividend of $0.1101 per share. This is a positive change from SPDR S&P Biotech’s previous quarterly dividend of $0.02. The ex-dividend date is Friday, June 16th. This represents a $0.44 annualized dividend and a dividend yield of 0.59%.

ILLEGAL ACTIVITY NOTICE: “Stock Traders Buy High Volume of Put Options on SPDR S&P Biotech (XBI)” was first reported by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at

About SPDR S&P Biotech

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with's FREE daily email newsletter.

Leave a Reply